Literature DB >> 28846070

Proteasome activity regulates CD8+ T lymphocyte metabolism and fate specification.

Christella E Widjaja1, Jocelyn G Olvera1, Patrick J Metz1, Anthony T Phan2, Jeffrey N Savas3, Gerjan de Bruin4, Yves Leestemaker5,6, Celia R Berkers7, Annemieke de Jong5, Bogdan I Florea4, Kathleen Fisch8, Justine Lopez1, Stephanie H Kim1, Daniel A Garcia1, Stephen Searles9, Jack D Bui9, Aaron N Chang8, John R Yates3, Ananda W Goldrath2, Hermen S Overkleeft4, Huib Ovaa5,6, John T Chang1.   

Abstract

During an immune response, CD8+ T lymphocytes can undergo asymmetric division, giving rise to daughter cells that exhibit distinct tendencies to adopt terminal effector and memory cell fates. Here we show that "pre-effector" and "pre-memory" cells resulting from the first CD8+ T cell division in vivo exhibited low and high rates of endogenous proteasome activity, respectively. Pharmacologic reduction of proteasome activity in CD8+ T cells early during differentiation resulted in acquisition of terminal effector cell characteristics, whereas enhancement of proteasome activity conferred attributes of memory lymphocytes. Transcriptomic and proteomic analyses revealed that modulating proteasome activity in CD8+ T cells affected cellular metabolism. These metabolic changes were mediated, in part, through differential expression of Myc, a transcription factor that controls glycolysis and metabolic reprogramming. Taken together, these results demonstrate that proteasome activity is an important regulator of CD8+ T cell fate and raise the possibility that increasing proteasome activity may be a useful therapeutic strategy to enhance the generation of memory lymphocytes.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28846070      PMCID: PMC5617668          DOI: 10.1172/JCI90895

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  63 in total

1.  A single naive CD8+ T cell precursor can develop into diverse effector and memory subsets.

Authors:  Christian Stemberger; Katharina M Huster; Martina Koffler; Florian Anderl; Matthias Schiemann; Hermann Wagner; Dirk H Busch
Journal:  Immunity       Date:  2007-12       Impact factor: 31.745

Review 2.  IRF4 at the crossroads of effector T-cell fate decision.

Authors:  Magdalena Huber; Michael Lohoff
Journal:  Eur J Immunol       Date:  2014-06-16       Impact factor: 5.532

3.  The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation.

Authors:  Ruoning Wang; Christopher P Dillon; Lewis Zhichang Shi; Sandra Milasta; Robert Carter; David Finkelstein; Laura L McCormick; Patrick Fitzgerald; Hongbo Chi; Joshua Munger; Douglas R Green
Journal:  Immunity       Date:  2011-12-23       Impact factor: 31.745

4.  The proteasome inhibitor bortezomib inhibits T cell-dependent inflammatory responses.

Authors:  Koichi Yanaba; Ayumi Yoshizaki; Eiji Muroi; Toshihide Hara; Fumihide Ogawa; Kazuhiro Shimizu; Shinichi Sato
Journal:  J Leukoc Biol       Date:  2010-04-23       Impact factor: 4.962

5.  The proteasome inhibitor bortezomib enhances the susceptibility to viral infection.

Authors:  Michael Basler; Christoph Lauer; Ulrike Beck; Marcus Groettrup
Journal:  J Immunol       Date:  2009-10-19       Impact factor: 5.422

Review 6.  Recognition and processing of ubiquitin-protein conjugates by the proteasome.

Authors:  Daniel Finley
Journal:  Annu Rev Biochem       Date:  2009       Impact factor: 23.643

7.  Primer-BLAST: a tool to design target-specific primers for polymerase chain reaction.

Authors:  Jian Ye; George Coulouris; Irena Zaretskaya; Ioana Cutcutache; Steve Rozen; Thomas L Madden
Journal:  BMC Bioinformatics       Date:  2012-06-18       Impact factor: 3.169

8.  PDK1 regulation of mTOR and hypoxia-inducible factor 1 integrate metabolism and migration of CD8+ T cells.

Authors:  David K Finlay; Ella Rosenzweig; Linda V Sinclair; Carmen Feijoo-Carnero; Jens L Hukelmann; Julia Rolf; Andrey A Panteleyev; Klaus Okkenhaug; Doreen A Cantrell
Journal:  J Exp Med       Date:  2012-11-26       Impact factor: 14.307

9.  Bcl-6 directly represses the gene program of the glycolysis pathway.

Authors:  Kenneth J Oestreich; Kaitlin A Read; Sarah E Gilbertson; Kenneth P Hough; Paul W McDonald; Veena Krishnamoorthy; Amy S Weinmann
Journal:  Nat Immunol       Date:  2014-09-07       Impact factor: 25.606

10.  Asymmetric inheritance of mTORC1 kinase activity during division dictates CD8(+) T cell differentiation.

Authors:  Kristen N Pollizzi; Im-Hong Sun; Chirag H Patel; Ying-Chun Lo; Min-Hee Oh; Adam T Waickman; Ada J Tam; Richard L Blosser; Jiayu Wen; Greg M Delgoffe; Jonathan D Powell
Journal:  Nat Immunol       Date:  2016-04-11       Impact factor: 25.606

View more
  18 in total

1.  T cells: Proteasome dictates CD8+ T cell fate.

Authors:  Shimona Starling
Journal:  Nat Rev Immunol       Date:  2017-09-11       Impact factor: 53.106

2.  Impaired enolase 1 glycolytic activity restrains effector functions of tumor-infiltrating CD8+ T cells.

Authors:  Lelisa F Gemta; Peter J Siska; Marin E Nelson; Xia Gao; Xiaojing Liu; Jason W Locasale; Hideo Yagita; Craig L Slingluff; Kyle L Hoehn; Jeffrey C Rathmell; Timothy N J Bullock
Journal:  Sci Immunol       Date:  2019-01-25

3.  Cellular and molecular profiling of T-cell subsets at the onset of human acute GVHD.

Authors:  Eleonora Latis; David Michonneau; Claire Leloup; Hugo Varet; Régis Peffault de Latour; Elisabetta Bianchi; Gérard Socié; Lars Rogge
Journal:  Blood Adv       Date:  2020-08-25

4.  Early precursors and molecular determinants of tissue-resident memory CD8+ T lymphocytes revealed by single-cell RNA sequencing.

Authors:  Nadia S Kurd; Zhaoren He; Tiani L Louis; J Justin Milner; Kyla D Omilusik; Wenhao Jin; Matthew S Tsai; Christella E Widjaja; Jad N Kanbar; Jocelyn G Olvera; Tiffani Tysl; Lauren K Quezada; Brigid S Boland; Wendy J Huang; Cornelis Murre; Ananda W Goldrath; Gene W Yeo; John T Chang
Journal:  Sci Immunol       Date:  2020-05-15

5.  Proteasome complexes experience profound structural and functional rearrangements throughout mammalian spermatogenesis.

Authors:  Dušan Živković; Angelique Sanchez Dafun; Thomas Menneteau; Adrien Schahl; Sandrine Lise; Christine Kervarrec; Ana Toste Rêgo; Paula C A da Fonseca; Matthieu Chavent; Charles Pineau; Odile Burlet-Schiltz; Julien Marcoux; Marie-Pierre Bousquet
Journal:  Proc Natl Acad Sci U S A       Date:  2022-04-04       Impact factor: 12.779

Review 6.  Role of Polyamines in Immune Cell Functions.

Authors:  Rebecca S Hesterberg; John L Cleveland; Pearlie K Epling-Burnette
Journal:  Med Sci (Basel)       Date:  2018-03-08

Review 7.  Immuno-Oncology: Emerging Targets and Combination Therapies.

Authors:  Henry T Marshall; Mustafa B A Djamgoz
Journal:  Front Oncol       Date:  2018-08-23       Impact factor: 6.244

8.  An engineered, quantifiable in vitro model for analysing the effect of proteostasis-targeting drugs on tissue physical properties.

Authors:  Sandra Loaiza; Silvia A Ferreira; Tamara M Chinn; Alex Kirby; Elena Tsolaki; Camilla Dondi; Katarzyna Parzych; Adam P Strange; Laurent Bozec; Sergio Bertazzo; Martin A B Hedegaard; Eileen Gentleman; Holger W Auner
Journal:  Biomaterials       Date:  2018-08-21       Impact factor: 12.479

Review 9.  A Sentinel in the Crosstalk Between the Nervous and Immune System: The (Immuno)-Proteasome.

Authors:  Fiona Limanaqi; Francesca Biagioni; Anderson Gaglione; Carla Letizia Busceti; Francesco Fornai
Journal:  Front Immunol       Date:  2019-03-29       Impact factor: 7.561

10.  Reiterative Enrichment and Authentication of CRISPRi Targets (REACT) identifies the proteasome as a key contributor to HIV-1 latency.

Authors:  Zichong Li; Jun Wu; Leonard Chavez; Rebecca Hoh; Steven G Deeks; Satish K Pillai; Qiang Zhou
Journal:  PLoS Pathog       Date:  2019-01-15       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.